Trial Profile
A Phase III Clinical Trial Comparing TC to TAC for Women with<BR>Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Pegfilgrastim
- Indications Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 13 Apr 2022 Status changed from active, no longer recruiting to completed.
- 26 May 2018 This trial has been completed in Ireland as per Eudra.
- 06 Feb 2013 Additional lead trial centre identified as reported by M.D. Anderson Cancer Center.